Table 6.
Analysis of pro- and anti-inflammatory markers (mortality)
| Pro- and Anti-Inflammatory Markers | Patients Alive at 1 yr, d0 | Patients Dead at 1 yr, d0 | P Value | Patients Alive at 1 yr, d3 | Patients Dead at 1 yr, d3 | P Value |
|---|---|---|---|---|---|---|
| MIF, median (Q1, Q3), pg/ml | 16,227.0 (9778.2, 42,386.4) | 19,912.8 (9759.6, 46,549.8) | 0.81 | 10,730.4 (4699.8, 16,597.2) | 9715.2 (5549.4, 24,394.2) | 0.63 |
| IL-6, median (Q1, Q3), pg/ml | 982.5 (319.4, 2010.6) | 985.8 (329.4, 2033.5) | 0.92 | 261.4 (100.9, 670.4) | 260.9 (89.7, 647.9) | 0.85 |
| IL-8, median (Q1, Q3), pg/ml | 255.2 (94.1, 538.5) | 315.0 (94.8, 543.8) | 0.43 | 61.7 (27.0, 110.6) | 46.0 (26.8, 125.7) | 0.90 |
| IL-10, median (Q1, Q3), pg/ml | 42.8 (17.8, 120.4) | 55.8 (19.7, 251.0) | 0.20 | 16.5 (9.7, 37.1) | 18.0 (9.6, 56.4) | 0.39 |
| IL-18, median (Q1, Q3), pg/ml | 575.5 (309.7, 1220.5) | 589.8 (297.1, 1383.7) | 0.85 | 564.9 (296.8, 1449.5) | 582.1 (310.6, 1708.7) | 0.51 |
| TNFR-1, median (Q1, Q3), pg/ml | 1707.6 (1165.6, 2210.4) | 1745.2 (1122.4, 2507.3) | 0.76 | 1558.6 (951.6, 2493.6) | 2019.4 (1315.7, 3086.1) | 0.03 |
| TNFR-2, median (Q1, Q3), pg/ml | 21,180.0 (14,411.3, 26,980.0) | 19,118.4 (12,878.4, 30,340.0) | 0.81 | 20,220.0 (12,126.8, 31,420.0) | 25,290.0 (17,809.1, 40,475.0) | 0.03 |
d0, Blood samples were drawn at the time of randomization; d3, blood samples were drawn 72 h after randomization.